Exon skipping, an approach targeting affected exons with predesigned antisense oligonucleotides (AONs) to produce a shorter but working version of dystrophin, can treat 55% of DMD patients [8]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.